Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug GS101 takes on dupixent in major trial

NCT ID NCT07386743

Not yet recruiting Disease control Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial compares a new injectable drug, GS101, to the established treatment Dupixent for adults with moderate-to-severe atopic dermatitis (eczema). About 572 participants will receive either GS101 or Dupixent every other week for a year. The main goal is to see if GS101 can reduce eczema severity by at least 75% after 16 weeks, matching Dupixent's performance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GS101 injection (a biologic drug similar to Dupixent)
What this could lead to
If GS101 works as well as Dupixent, it could offer another treatment option for people with moderate-to-severe eczema.
What could go wrong
This is a head-to-head comparison, not a new breakthrough. GS101 may not be as effective or safe as Dupixent. Results are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Hospital of China Medical University

    Shenyang, Liaoning, 110001, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.